A case report described a patient with aggressive mismatch repair-deficient prostate cancer, characterized by a somatic co-deletion of EPCAM, MSH2, and MSH6, who achieved a complete radiographic response to pembrolizumab within three months, along with a significant drop in PSA levels. This evidence concerns the gene MSH2 and prostate carcinoma.